Deans' stroke musings: Stemedica announces clinical trial for IV stem cell treatment for chronic ischemic stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, May 12, 2023

Stemedica announces clinical trial for IV stem cell treatment for chronic ischemic stroke

What do you think are the chances of your doctor and hospital following this? First they have to know it is occurring. I'd say there is zero chance.

But why go thru all the trouble of stem cells if exosomes are the reason for the benefits? Which must be why no one seems to be monitoring stem cell survival.

Application of stem cell-derived exosomes in ischemic diseases: opportunity and limitations

The latest here:

Stemedica announces clinical trial for IV stem cell treatment for chronic ischemic stroke

Stemedica Cell Technologies announced the launch of a phase 2b/3 clinical trial to assess the safety, efficacy and tolerability of a single IV injection of allogenic mesenchymal stem cells in patients with chronic ischemic stroke.

According to a release from the company, the multicenter, randomized, double-blind study is expected to enroll approximately 300 individuals, who will be divided into two cohorts and receive either a single injection of allogeneic mesenchymal stem cells and standard treatment or placebo and standard treatment.

Image of brain with ischemic stroke — Stemedica Cell Technologies announced the launch of a phase 2b/3 clinical trial of its IV allogenic mesenchymal stem cell treatment for patients with chronic ischemic stroke. *Source: Adobe Stock*

The study will assess improvements in clinical outcomes of the upper-extremity of the body as measured on the Fugal-Meyer Scale from baseline through 6 months. Secondary study endpoints include change from baseline in the modified Rankin Scale and Barthel Index and safety and tolerability, the company stated.

“It is critical to address the enormous medical and social issues caused by approximately 10 million new cases of stroke each year around the world,” Nikolai Tankovich, MD, PhD, Stemedica president and chief medical officer, said in the release. “We are encouraged that Stemedica’s phase 2b/3 clinical trial under the FDA [investigational new drug] can validate the role that our ischemic tolerant mesenchymal stem cells can play in addressing this crisis.”

Stemedica reported positive results from a phase 1/2 study of the same therapeutic at three locations in Arizona and California. Trial data demonstrated an excellent safety profile, as well as statistically significant improvements in NIH Stroke Scale for neurological assessment, Barthel Index, Mini-Mental Status Exam for mental status and Geriatric Depression Scale for degree of depression, per the release.